-

Hinge Health Introduces Enso 3

FDA-cleared wireless pain relief device features reimagined hardware and updated software experience for personalized treatment

New study shows Enso outperforms traditional pain relief methods

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hinge Health is announcing Enso 3™, a patented, wireless device that is FDA-cleared and clinically-proven to reduce musculoskeletal pain. One in four people with chronic pain experience sudden spikes1 that often disrupt their daily activities and compel them to seek relief. The new Enso 3 delivers electrical nerve stimulation that achieves non-invasive, non-addictive pain relief within minutes. First shipments of the new Enso are starting this month, with wider availability to all new Hinge Health members starting in 2025.

“A musculoskeletal solution is incomplete without an effective way to help people overcome pain that disrupts their daily activities,” said Daniel Perez, CEO and co-founder of Hinge Health. “Over 100,000 Hinge Health members have benefitted from Enso to date, completing over 3.3 million treatment sessions. We’re thrilled to be shipping this unparalleled hardware-software medical solution to Hinge Health members, empowering them with the industry’s most advanced pain relief device that’s seamlessly integrated with the world’s leading exercise therapy program.”

The New Enso 3

Featuring reimagined hardware with new colors, finish, and materials, the small and light Enso 3 attaches to the skin with a reusable gel pad, making it comfortable to wear before exercise therapy or during daily activities affected by pain.

Enso 3 also introduces new, clinically-proven electrical waveforms customized to different body parts and pain levels. These waveforms are patterns of electrical signals programmed into Enso through software to relieve pain. In addition to the original waveform shown via a peer-reviewed study to reduce pain by over 50%, Enso 3 will ship with two new waveforms targeted at smaller muscles or for people with more sensitivity. Additionally, Enso 3 will deliver new treatments over time with over-the-air software updates, bringing to the device new waveforms released in the future.

To help with member guidance and progress tracking, new Enso 3 features have been integrated into the all-in-one Hinge Health app.

Study: Enso Vastly Outperforms Traditional Pain Relief Methods

In a recent randomized controlled trial involving 325 participants, Enso showed superior pain reduction compared to a traditional Transcutaneous Electrical Nerve Stimulation (TENS) device and exercise therapy alone.

  • After four weeks, among participants who consistently used their devices, people who used Enso alongside exercise therapy were 2.3 times more likely to achieve clinically meaningful pain reduction than those using traditional TENS devices alongside exercise therapy.
  • Enso, coupled with exercise therapy from Hinge Health, is 2.8 times more likely to achieve meaningful pain reduction than exercise therapy alone.
  • 48.8% of Enso users experienced significant pain improvement, compared to 34.6% of traditional TENS users and 35.9% of those using exercise therapy without Enso.

"These results demonstrate that Enso is a powerful tool for providing pain relief, enabling individuals to regain their mobility," said Dr. Amitabh Gulati, MD, Board-Certified Chronic Pain Specialist.2 "Hinge Health offers a robust suite of complementary tools, including the upgraded Enso 3, alongside digital exercise therapy, computer-guided movement feedback, and a comprehensive care team that are proven to help people reduce their reliance on opioids or injections."

About Hinge Health

Hinge Health is moving people beyond pain by transforming the way it is treated and prevented. We connect people, digitally and in-person, with expert clinical care. Using advanced technology and AI, a team of clinical experts guides people through personalized care directly from their phone. It is proven to reduce pain by 68%, prevent 42% of new opioid prescriptions, and avoid more than half of joint replacement surgeries. Available to 18M people, Hinge Health is trusted by leading health plans and employers, including Land O’Lakes, L.L. Bean, Salesforce, Self-Insured Schools of California, Southern Company, US Foods, and Verizon.

Learn more about how we are inspiring people to improve their health through the power of movement http://www.hingehealth.com.

_________________
1
Based on a 2024 internal analysis of Hinge Health data on chronic program participants.
2 Dr. Gulati is a member of Hinge Health’s Clinical Advisory Board and an author of this study.

Hinge Health


Release Versions

More News From Hinge Health

Hinge Health Reduces MRIs and X-Rays for Back Pain by 60%

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced a new study showing that participants in its chronic back pain program had substantially fewer imaging visits, such as X-rays and MRIs, compared to a similar group of individuals who sought traditional PT care. The peer-reviewed study, published in The Journal of Health Economics and Outcomes Research found that of the 4,330 participants, those who used Hinge Health had 60% fewer imaging visits for low back pain at...

Hinge Health announces $250 million share repurchase program

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced that its board of directors has authorized a $250 million share repurchase program. “During the first three quarters of 2025, we generated $108 million in cash from operations and $118 million in free cash flow1, reflecting the strength and scalability of our business model,” said James Budge, CFO, Hinge Health. “We maintain a robust balance sheet, with nearly $500 million in cash and investments as of the end of Q3...

Hinge Health reports third quarter 2025 financial results

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2025. “With healthcare costs rising dramatically, our mission to automate care delivery has never been more urgent,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “This quarter we surpassed 1.5 million lifetime members, delivered year-over-year revenue growth of 53%, and generated record free cash flow. Our AI-powered platform is transforming care at...
Back to Newsroom